| Date Filed | Type | Description |
| 09/28/2023 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 08/15/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
4
| LAUER REGAN J (Chief Accounting Officer) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Exercised 21,030 restricted stock units
@ $0 |
|
| 06/15/2023 |
4
| Selecky Christobel (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Granted 158,263 options to buy
@ $2.99, valued at
$473.2k
|
|
| 06/15/2023 |
4
| MAXWELL LINDA (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Granted 158,263 options to buy
@ $2.99, valued at
$473.2k
|
|
| 06/15/2023 |
4
| Cohen Cheryl (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Granted 158,263 options to buy
@ $2.99, valued at
$473.2k
|
|
| 06/15/2023 |
4
| Clark Wesley (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Granted 158,263 options to buy
@ $2.99, valued at
$473.2k
|
|
| 06/15/2023 |
4
| Brennan John Owen (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Granted 158,263 options to buy
@ $2.99, valued at
$473.2k
|
|
| 06/15/2023 |
4
| BLASZYK MICHAEL D (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Granted 158,263 options to buy
@ $2.99, valued at
$473.2k
|
|
| 06/05/2023 |
4
| Clark Wesley (Director) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Bought 7,000 shares
@ $2.91, valued at
$20.4k
|
|
| 05/22/2023 |
SC 13D/A
| Cambridge Equities, LP reports a 77.3% stake in ImmunityBio, Inc. |
| 05/16/2023 |
4
| SOON-SHIONG PATRICK (See remarks) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Bought convertible notes
@ $2.28, valued at
$0 |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/01/2023 |
3/A
| Clark Wesley (Director) has filed a Form 3/A on ImmunityBio, Inc. |
| 02/14/2023 |
8-K
| Results of Operations and Financial Condition Interactive Data |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/07/2023 |
4
| Adcock Richard (CEO & President) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Paid exercise price by delivering 42,192 shares
@ $4.33, valued at
$182.7k
Exercised 83,333 restricted stock units
@ $0 |
|
| 01/04/2023 |
4
| Sachs David C. (CFO) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Exercised 7,598 restricted stock units
@ $0 |
|
| 01/04/2023 |
4
| Adcock Richard (CEO & President) has filed a Form 4 on ImmunityBio, Inc.|
Txns:
| Paid exercise price by delivering 4,273 shares
@ $5.07, valued at
$21.7k
Exercised 8,620 restricted stock units
@ $0 |
|
| 12/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obl... |
| 12/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/12/2022 |
S-3MEF
| Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]: |
|